Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

7 Volatile Stocks That Could Be the Next GME

By Chris Lau, InvestorPlace Contributor

These seven volatile stocks could produce returns that rival GameStop. Investors should keep their eyes on what could be the next GME.

Fisker Could Take Market Share From Tesla, Boosting FSR Stock

By Chris Lau, InvestorPlace Contributor

FSR stock looks like a bargain, since its market capitalization is much lower than those of its competitors, including Nio and Tesla.

Only Buy CCIV Stock If You’ll Hold It For At Least 5 Years

By Chris Lau, InvestorPlace Contributor

Churchill Capital is not suitable for the short-term investor, as the Lucid acquisition will take a few years to book profits for CCIV stock.

Avoid Hyliion Holdings Stock Even If the Clean Energy Bubble Begins to Reinflate

By Chris Lau, InvestorPlace Contributor

Hyliion only rose because of the clean energy bubble as it posted no revenue in the last quarter.

Bet on Blockbuster Movies Lifting AMC Entertainment in 2021

By Chris Lau, InvestorPlace Contributor

Blockbuster releases from Disney and Warner Bros, plus the vaccine rollout are positive catalysts for AMC stock.

Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks

By Chris Lau, InvestorPlace Contributor

Nearly everyone will get the Covid-19 vaccination, suggesting strong revenue for a handful of pharmaceutical companies.

Ripple Is a Great Long-Term Buy No Matter What Happens With the SEC

By Chris Lau, InvestorPlace Contributor

The SEC’s suit against Ripple is a regulatory risk hurting XRP stock in the short-term, while Bitcoin soars to record highs.

Ideanomics Still Looks Really Compelling as a Bet on EV Growth

By Chris Lau, InvestorPlace Contributor

Investors are speculating that Ideanomics will carve a niche in underserved EV markets like agriculture and motorbikes.

QuantumScape’s Long-term Battery Prospects Will Hold Charge

By Chris Lau, InvestorPlace Contributor

QuantumScape's deal with VW, which injects $100 million, plus the advanced technologies, is is one of many reasons to hold QS Stock.

7 Best Stocks on the Nasdaq

By Chris Lau, InvestorPlace Contributor

Investors need to hold the best companies that money can buy on the Nasdaq, amid a growing weakness in the technology stock index.

Load More